Skip to main content
Skip to footer
Home
About us
Our Business
Strategy and business model
Management
Board of Directors
Contact us
Pipeline
Our Science
Pipeline overview
Projects
Rugocrixan
Fosrugocrixan
Business Development
IP
Publications
Therapeutic areas
Myocardial infarction
Ovarian cancer
Investors
Presentations
Press Releases
Financial Reports
Financial Calendar
Events
The Share
Sustainability
Corporate Governance
Articles of Association
Annual General Meeting
Board Committee
Board
CEO and Management
Auditors
Certified Adviser
Home
About us
Our Business
Strategy and business model
Management
Board of Directors
Contact us
Pipeline
Our Science
Pipeline overview
Projects
Rugocrixan
Fosrugocrixan
Business Development
IP
Publications
Therapeutic areas
Myocardial infarction
Ovarian cancer
Investors
Presentations
Press Releases
Financial Reports
Financial Calendar
Events
The Share
Sustainability
Corporate Governance
Articles of Association
Annual General Meeting
Board Committee
Board
CEO and Management
Auditors
Certified Adviser
Start
>
News
News
Data indicate broad utility of Kancera’s PFKFB3 inhibitors.
Kancera presents at Boston seminar April 27th, 2012.
Kanceras ROR project has been selected for presentation at the ASCO annual meeting in Chicago.
Kancera’s ROR inhibitors show superior efficacy in 3D pancreatic tumor model.
Full Year Report 2011 for Kancera AB (publ)
Kancera’s ROR-inhibitor provides higher specificity than competing products
Kancera file patents for ROR inhibitors against cancer
Kanceras strategy is given attention when global expertise in cancer gathers in Washington DC
iNovacia announces collaboration with Agios Pharmaceuticals
Kancera strengthens its patent portfolio in cancer metabolism
